AstraZeneca Pharma India on Tuesday reported a 23% decline in net profit to Rs 44.88 crore for the March quarter of FY26.
The company had reported a net profit of Rs 58.25 crore for the January-March quarter a year ago, according to a regulatory filing by AstraZeneca Pharma India, a biopharmaceutical company.
Its revenue climbed 20.42% to Rs 578.61 crore in the March quarter of FY26. It was Rs 480.48 crore a year ago.
Total expenses of AstraZeneca Pharma India in the March quarter grew 27.36% to Rs 525.34 crore.
For the entire FY26, AstraZeneca's net profit jumped 62% to Rs 187.52 crore.
Its total revenue rose 32.58% to Rs 2,275.58 crore for the financial year ended March 31.
The revenue growth was "supported by continued growth in Oncology and Biopharmaceuticals, as well as progress in Rare Disease", said an AstraZeneca Pharma statement.
Shares of AstraZeneca Pharma India on Tuesday closed at Rs 8,984.05 per scrip on BSE, up 2.14% from the previous close.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
